Lumida
/A
⌘K
Agilent Technologies Inc

Agilent Technologies Inc

A
$150.86USD↑+0.59%+0.88 today

MARKET CAP

41.4B

P/E (TTM)

33.4x

FWD P/E

—

DAY RANGE

$148 – $152

52W RANGE

$108
$164

AI Summary

Stalk
StalkMedium

A remains in an intact intermediate and long-term uptrend above rising 50- and 200-day SMAs, but short-term momentum has softened with price dipping below the 9- and 20-day EMAs. Low-volume pullback suggests a shallow correction rather than reversal, and support at ~150.5 followed by the rising 50-day SMA near ~142.3 offers selective accumulation zones. Medium-term bias stays bullish, but timing warrants patience until price shows acceptance off support before entering.

  • ↑Q2 2026 revenue $1.83 B, 6.3% core growth YoY
  • ↑EPS $1.49 (+14% YoY); operating margin rose to 26.4% via Ignite efficiencies
  • ↓Negative growth factor suggests challenges expanding revenues, soft academia/government demand
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Agilent Technologies, Inc. (NYSE: A) is a leading player in the life sciences and diagnostics markets, specializing in analytical instruments, software, services, and consumables that cater to pharmaceutical, environmental, and chemical industries. The company has evolved post its spin-off from Hewlett-Packard in 1999 to become a key partner in advancing healthcare through its diagnostics and life sciences solutions. Agilent is positioned well amid the ongoing trends in biotechnology and advanced materials, focusing on innovation to address complex market needs.

Bull says

  • ↑Q2 2026 revenue $1.83 B, 6.3% core growth YoY
  • ↑EPS $1.49 (+14% YoY); operating margin rose to 26.4% via Ignite efficiencies
  • ↑Raised FY26 revenue growth guide to 4.5%–6% and EPS to $6.00–$6.10
  • ↑AI integration with OpenAI and new 9500 ICP-MS drive innovation and market share
  • ↑Robust pharma and diagnostics demand; diversified end markets ensure resiliency
  • ↑High earnings yield, positive analyst revisions, and attractive book-to-price valuation

Bear says

  • ↓Negative growth factor suggests challenges expanding revenues, soft academia/government demand
  • ↓Low 13F ownership and rising short interest indicate institutional skepticism
  • ↓Inflation, tariff pressures and elevated leverage risk debt refinancing and margins
  • ↓Execution risk on new AI integrations and product launches without proven traction
  • ↓High volatility factor could trigger sharp price swings and investor uncertainty
  • ↓Cautious customer spending, notably in government funding, may dampen future demand

Investment themes with A

SPY↑ +0.09%

NVDA · AAPL · GOOGL
Medical Devices↑ +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 08-27-2026neutral

Transcript signals

Bull points

  • With me are Porek McDonald, Agilent President and CEO, and Rodney Gonzalez, Agilent Vice President and Interim CFO.
  • Joining the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group, Angelica Ryman, President of the Agilent Cross Lab Group, and Mike Zhang, President of the Applied Markets Group.
  • This presentation is being webcast live.

Bear points

  • During this call, we will also make forward-looking statements about the financial performance of the company.
  • These statements are subject to risk and uncertainty and are only valid as of today.
  • The company assumes no obligation to update them.
Read full transcript analysis ›